**Jingxin Pharmaceutical refiles for Hong Kong IPO as generic drug sales decline and innovation pivot lags**
Jingxin Pharmaceutical, a Shenzhen-listed Chinese drugmaker, submitted a second application to list on the Hong Kong Stock Exchange on September 18, 2026, after its initial February filing lapsed. The company aims to raise funds for R&D and marketing as it transitions from declining generic drug sales to innovative drugs. Its only approved Class 1 innovative drug, insomnia treatment Didasini, generated 195 million yuan in 2025 but faces growing competition. Revenue fell 2.14% in 2025 to 40.69 billion yuan, and net profit dropped 9.35% in the first half of 2026. The company also disclosed a tax penalty and declining production capacity utilization.
Reference imageEditorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Reporting timeline
Jingxin Pharmaceutical Plans Hong Kong IPO Amid Cash Needs and Innovation Drug Transition
Jingxin Pharmaceutical, a Chinese pharmaceutical company listed on the Shenzhen Stock Exchange since 2004, is pursuing an A+H dual listing by applying for an H-share IPO on the Hong Kong Stock Exchange. The company, which generated approximately 40 billion yuan in annual revenue from 2022 to 2025, faces financial pressure as its traditional generic drug business declines due to multiple rounds of centralized drug procurement (VBP). Its cash reserves of 485 million yuan are considered insufficient for the capital-intensive innovation drug R&D. The company's only approved Class 1 innovative drug, Didasini (for insomnia), generated 195 million yuan in 2025, accounting for 4.8% of revenue, but faces increasing competition from newly approved drugs. Its pipeline drug JX2201 (for lipid-lowering) is in early clinical stages. The article notes that Jingxin's generic drug production line utilization fell from 77% to 61% between 2023 and mid-2026, and its revenue declined 2.14% in 2025. The article attributes the view that the company's ability to successfully transform into an innovative drug company ultimately depends on its product pipeline.
Read sourceJingxin Pharmaceutical Plans Hong Kong IPO Amid Cash Needs and Innovation Drug Pivot
Jingxin Pharmaceutical, a Zhejiang-based drugmaker with annual revenue of about 40 billion yuan, is pursuing an A+H dual listing by updating its H-share listing application to the Hong Kong Stock Exchange on September 18, 2025. The company, which filed its initial application in February 2025, faces scrutiny over its financial needs and innovation credentials. As of mid-2025, Jingxin had 485 million yuan in cash and short-term debt of 183 million yuan, indicating manageable short-term liquidity. However, its cash position is considered insufficient for costly innovative drug R&D. The company's only approved Class 1 innovative drug, insomnia treatment Didasini (brand name Jingnuoning), generated 195 million yuan in 2025, up from 23.42 million yuan in 2024, but still accounts for less than 10% of revenue. Jingxin's core business remains generic and active pharmaceutical ingredients (API) drugs, which face declining sales and capacity utilization due to multiple rounds of centralized drug procurement (VBP). Revenue fell 2.14% in 2025 to 40.69 billion yuan, and net profit dropped 5.15% in the first half of 2026. The company's innovation pipeline includes early-stage lipid-lowering drug JX2201, which faces competition from established PCSK9 and siRNA products. Analysts note that while the Hong Kong listing is a step, it does not guarantee successful transformation into an innovative drug company.
Read sourceJingxin Pharma Files for Hong Kong IPO Again After 20 Years on Shenzhen Exchange
Jingxin Pharmaceutical (京新药业), listed on the Shenzhen Stock Exchange for over 20 years, has submitted a second application to list on the Hong Kong Stock Exchange, with Citic Securities as the sole sponsor. The company's previous filing in February 2026 lapsed in August 2026. The IPO aims to fund R&D for products and pipeline drugs, strengthen marketing networks, and expand market presence in key therapeutic areas. According to the prospectus, Jingxin reported revenues of 39.99 billion yuan (2023), 41.59 billion yuan (2024), 40.69 billion yuan (2025), and 19.87 billion yuan (first half 2026), with profits of 6.23 billion, 7.19 billion, 7.72 billion, and 3.58 billion yuan respectively. The company has faced impairment charges on acquisitions and associates, declining capacity utilization rates across its generic drug and traditional Chinese medicine production lines, and a tax penalty in 2024 for improper R&D expense classification and failure to withhold personal income tax. Jingxin's innovative drug Didezini (京诺宁), approved in November 2023 and included in the national medical insurance catalog in November 2024, generated sales of 1.95 billion yuan in 2025 and 1.53 billion yuan in the first half of 2026. The company did not respond to interview requests from the reporter.
Read sourceShow 3 older updatesHide older updates
Jingxin Pharma Files for Hong Kong IPO After 20 Years on Shenzhen Bourse
Jingxin Pharmaceutical (SZ002020), a Shenzhen-listed company for over 20 years, has submitted a second application to list on the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor. The company aims to raise funds for R&D of products and pipeline drugs, strengthen its marketing network, and expand in key therapeutic areas. Its prospectus shows revenue of 39.99 billion yuan in 2023, 41.59 billion in 2024, 40.69 billion in 2025, and 19.87 billion in the first half of 2026, with net profits of 6.23 billion, 7.19 billion, 7.72 billion, and 3.58 billion respectively. However, the company faces challenges including declining capacity utilization rates for its generic drug and traditional Chinese medicine production lines, impairment losses on investments and goodwill, and a tax penalty of 800,000 yuan in 2024 for underpayment of corporate and personal income taxes. R&D costs and sales expenses remain high, though sales service fees are declining as more generics are included in national volume-based procurement.
Read sourceJingxin Pharma Files Again for Hong Kong IPO, Betting on Single Insomnia Drug for Innovation Story
Jingxin Pharmaceutical (002020.SZ), a Chinese pharmaceutical company listed on the A-share market for over 20 years, has filed a second time for a Hong Kong IPO, with CITIC Securities as the sole sponsor. The company's first filing in February 2026 lapsed after six months. The updated prospectus includes first-half 2026 data, revealing a stable financial base but diverging growth drivers. Revenue was 19.87 billion yuan in H1 2026, with a profit of 3.58 billion yuan, both declining year-on-year. The company's innovation story hinges almost entirely on Didasini (Jingnuoning), its only approved innovative drug, a Class 1 insomnia treatment launched in November 2023 and included in the national medical insurance catalog in November 2024. Sales reached 1.95 billion yuan in 2025 and exceeded 1.5 billion yuan in H1 2026. However, the insomnia treatment market faces intensifying competition from newer dual orexin receptor antagonists like lemborexant and daridorexant. The company's R&D spending has been declining, from 4.01 billion yuan in 2023 to 1.65 billion yuan in H1 2026, raising questions about its commitment to innovation. The IPO proceeds are planned for R&D, marketing, potential acquisitions, and working capital. Market observers expect the H-share price may trade at a discount to the A-share price, given the mixed valuation of generics and innovative drug pipelines in Hong Kong.
Read sourceJingxin Pharma Reports H1 2026 Revenue and Profit Decline, Files Second Hong Kong IPO Application
Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) has submitted a second application to list on the Hong Kong Stock Exchange's main board, following the lapse of its initial filing in February. The company, an A-share listed firm for over 20 years, is navigating a challenging transition from its core generic drug business, which faces growth stagnation due to volume-based procurement price cuts, toward innovative drug development. According to its prospectus, revenue remained nearly flat from 2023 to 2025, and in the first half of 2026, revenue fell 1.46% year-on-year to 1.987 billion yuan, while net profit dropped 9.35% to 352 million yuan. The company's only approved Class 1 innovative drug, Didasini (for insomnia), generated 195 million yuan in 2025 sales but faces increasing competition from newly approved rivals. Jingxin's profit growth in prior years was achieved through cost-cutting, reducing sales and R&D expenses, a strategy that appears to have reached its limit. Additionally, the company disclosed a tax penalty of 800,000 yuan in December 2024 for improper R&D expense classification and failure to withhold personal income tax. Analysts cited in the report note that the company's R&D spending, at about 10% of revenue, is below the typical 15-20% for innovative drug firms, explaining the slow pipeline progress. The success of its 'A+H' capital strategy and transformation will depend on the sales ramp of Didasini, the advancement of its Lp(a) candidate JX2201, and the sustainability of its cost-control measures.